129 related articles for article (PubMed ID: 17653664)
1. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
2. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
4. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
6. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
8. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
9. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
Guo XF; Zhong GS; Miao QF; Zhen YS
Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
[TBL] [Abstract][Full Text] [Related]
10. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
11. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
12. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
[TBL] [Abstract][Full Text] [Related]
13. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.
Zhong GS; Guo XF; Zhang SH; Zhen YS
Biomed Environ Sci; 2011 Dec; 24(6):602-7. PubMed ID: 22365395
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.
Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS
World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase.
Fengqiang W; Boyang S; Yongsu Z
Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
Wang FQ; Shang BY; Zhen YS
Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
[TBL] [Abstract][Full Text] [Related]
19. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]